20:36:51 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Bio-Works Technologies är verksamma inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.


2023-02-17 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-20 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-24 Ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 Årsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 Ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 Ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2021-09-03 09:00:00

Bio-Works Technologies AB (Uppsala, Sweden) and BIA d.o.o. (Ljubljana, Slovenia) have signed a distribution agreement through which BIA will provide Bio-Works' next generation chromatography resins and prepacked columns to customers in Croatia and Slovenia. 

Bio-Works' patented resins, WorkBeads™, are well-suited not only for the purification of biological compounds at laboratory scale but also for biopharmaceuticals at large scale, including peptides and recombinant proteins. Bio-Works has a broad portfolio of resin technology, including immobilized affinity chromatography (IMAC), size exclusion chromatography (SEC), affinity chromatography (AC) and ion exchange (IEX) resins.

Rok Stravs, Director at BIA, commented on the agreement, "We are excited to work with Bio-Works to help our customers with top quality biochromatography resins. There are production and R&D sites of global biopharmaceutical players (e.g. Novartis, Pfizer) in Slovenia and Croatia where we see also interesting development in the field of therapeutic peptides. Therefore, Bio-Works' products are a perfect fit to our existing portfolio."

BIA Ltd. is located in Ljubljana, Slovenia and has been selling laboratory consumables and instruments to customers in the pharma industry and research organisations for more than 30 years. Their two most important fields of activity are chromatography and biotechnology.

Jonathan Royce, CEO of Bio-Works, said "We strongly believe that BIA is the right partner for BIo-Works in Croatia and Slovenia. These markets are rapidly growing, and BIA can provide local, high quality support to the pharma and biotech companies who are establishing research and production facilities here. BIA's has a long track record serving the biopharmaceutical industry, and their company values are well-aligned with Bio-Works' own beliefs of caring about and engaging with the customers that we serve."